Search Results

) predominantly spiritual suffering, (4) rapidly increasing suffering, and (5) persistently high suffering ( Figure 1 ). Table 1. Patient Characteristics Figure 1. Trajectories of psychological, spiritual, physical, and functional suffering during

noncompleters had a distress score >3; chi-square, P =.049). Abbreviations: T0, baseline; T1, pretreatment; T2, posttreatment; T3, follow-up. Patient- and disease-related characteristics were distributed equally between the study groups ( Tables 2 and 3

. Characteristics of 2019 Positive Coverage Policies by Payer Table 3. Coverage Clinical Scenarios by Private Payer and Medicare We found wide variation in how payers structured their policies—that is, whether the policy focused on the technology generally or on a

Survey” had 3 components: (1) oncologist demographics and practice characteristics, (2) oncologist ratings of their beliefs about and confidence with management of common geriatric issues, and (3) 1 of 8 randomly assigned clinical vignettes. The beliefs

and recommend specific validated instruments and to examine the correlation of these domains with patient outcomes. Characteristics and Treatments In addition to harmonizing outcome measures, the workgroup identified characteristics of the patient

used SEER variables to obtain patient demographics and tumor characteristics at diagnosis, and used claims to identify characteristics of the index inpatient stay, prior health conditions, and healthcare services received, and to generate the Charlson

they believe their recommendations are guideline-compliant; and 3) do attitudes, familiarity, use, or compliance with guidelines differ by specialty or other physician characteristics? Methods This study was approved by the University of Michigan

studying the relationship between pharmaceutical plan characteristics and choice of therapy. For most postmenopausal women with hormone receptor–positive (HR+) disease there are essentially 2 options for oral endocrine therapy: tamoxifen, whose efficacy was

availability of clinical trials, 13 supported research efforts only 12% of the time. Figure 3. (A) Duration of support of protected time for research, (B) funding sources for protected time for research, and (C) characteristics of incentive plans for ACs and

care postsurgery. Sociodemographic and clinical characteristics were examined as covariates. Demographic Characteristics Participants reported their age, sex, race/ethnicity, education level, and insurance status. Clinical Characteristics